
Why the FTC Issued a Second Request on the Aya–Cross Country Merger
FTC scrutiny of the Aya–Cross Country merger highlights risks of MSP consolidation in healthcare staffing and why hospitals need independent workforce control.
FTC scrutiny of the Aya–Cross Country merger highlights risks of MSP consolidation in healthcare staffing and why hospitals need independent workforce control.
The healthcare staffing industry may be on the cusp of another major consolidation with the potential acquisition of Cross Country Healthcare by Aya Healthcare.
In December 2024, Aya Healthcare announced plans to go through with an acquisition of Cross Country Healthcare (Nasdaq: CCRN) in an all-cash deal valued at $615 million, or $18.61 per share. This represented a 67% premium over Cross Country’s pre-announcement closing price of $11.16. The announcement initially lifted CCRN’s stock
A key principle in analyzing business strategies is the time-tested adage: “Follow the money.” This approach is particularly relevant when examining the current landscape in Washington and its potential effects on the healthcare staffing sector. While it might seem unusual to link government actions to healthcare staffing, understanding the flow
How can hospitals hold on to nurses, bring new ones into the fold, and fend off extreme staffing shortages?
Let’s talk about the nursing shortage.
The holidays are notoriously difficult on medical facilities. And this holiday season should be no exception with the pandemic still lingering. As noted by Kelly Gooch of Becker’s Hospital Review, there are many unprecedented challenges in healthcare staffing that have made it more and more difficult to provide the care that patients
BlueSky Synergy announced today its formal release of BlueSky Medical Staffing Software Version 5.18. Due to the recent rise in travel nurse staffing rates, the technology released today becomes the first platform to provide hospitals complete control of subcontractor relationships.
Johnson & Johnson on Tuesday announced it had submitted data to the Food and Drug Administration for authorization of a booster shot of its single-dose COVID-19 vaccine, marking the latest effort by vaccine makers to gain approval for a new round of inoculations.